Cargando…

Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists

Objective: The aim of this survey conducted by 20 leading Spanish oncologists was to analyze the concurrence between Spanish clinical practice and the recently published definition of the optimal sequence for the systemic treatment of metastatic breast cancer (MBC) according to patient profiles. Met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sánchez-Rovira, Pedro, Zamora, Pilar, Salvador-Bofill, Javier, Morales, Serafín, Martínez-Jáñez, Noelia, Martínez-de-Dueñas, Eduardo, Lluch, Ana, Illarramendi, José Juan, Gómez-Pardo, Patricia, Gavilá Gregori, Joaquín, García-Palomo, Andrés, García-Mata, Jesús, Fernández, Yolanda, del Barco, Sonia, de Juan, Ana, Ciruelos, Eva, Chacón, José Ignacio, Calvo, Lourdes, Barnadas, Agustí, Albanell, Joan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493326/ https://www.ncbi.nlm.nih.gov/pubmed/31069129 http://dx.doi.org/10.1080/21556660.2019.1604375

Ejemplares similares

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
por: Gil-Gil, Miguel J., et al.
Publicado: (2021)

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alba, Emilio, et al.
Publicado: (2016)

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
por: Salvador Bofill, Javier, et al.
Publicado: (2022)

Defining the optimal sequence for the systemic treatment of metastatic breast cancer
por: Mestres, J. A., et al.
Publicado: (2016)

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
por: Rincón, Raúl, et al.
Publicado: (2015)

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
por: Gavilá, Joaquín, et al.
Publicado: (2019)

Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval
por: Ciruelos, Eva, et al.
Publicado: (2019)

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
por: Cabello, Paula, et al.
Publicado: (2023)

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
por: Muntasell, Aura, et al.
Publicado: (2017)

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
por: Ayala de la Peña, Francisco, et al.
Publicado: (2023)

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
por: Tormo, Eduardo, et al.
Publicado: (2019)

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
por: Tormo, Eduardo, et al.
Publicado: (2017)

SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
por: Chacón López-Muñiz, J. I., et al.
Publicado: (2019)

MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma
por: Pattanayak, Birlipta, et al.
Publicado: (2020)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
por: Alba, E, et al.
Publicado: (2014)

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
por: Tibau, Ariadna, et al.
Publicado: (2023)

Preventive treatments for breast cancer: recent developments
por: Alés-Martínez, J. E., et al.
Publicado: (2014)

Avascular necrosis of the proximal epiphysis of the first metatarsal bone in childhood. Long-term outcome
por: García-Mata, Serafín
Publicado: (2023)

The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models
por: Sanz-Álvarez, Marta, et al.
Publicado: (2021)

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
por: Lluch, Ana, et al.
Publicado: (2020)

The role of the oncologist
por: Rossi, M, et al.
Publicado: (2010)

MO22-2 Thromboembolic events associated to COVID-19 in a breast cancer cohort during the most recent waves of the disease
por: Illarramendi, Jorge, et al.
Publicado: (2022)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Assessment of Patient Attribution to Care From Medical Oncologists, Surgeons, or Radiation Oncologists After Newly Diagnosed Cancer
por: Gondi, Suhas, et al.
Publicado: (2021)

Enzyme/Nanocopper Hybrid Nanozymes: Modulating Enzyme-like Activity by the Protein Structure for Biosensing and Tumor Catalytic Therapy
por: Losada-Garcia, Noelia, et al.
Publicado: (2021)

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study
por: de Dueñas, Eduardo Martínez, et al.
Publicado: (2014)

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
por: Schmid, Peter, et al.
Publicado: (2023)

Graphene-TLL-Cu(2)ONPs Hybrid as Highly Efficient Catalyst for Degradation of Organic Compounds
por: Losada-Garcia, Noelia, et al.
Publicado: (2023)

Cancer During Pregnancy: The Oncologist Overview
por: Hepner, Adriana, et al.
Publicado: (2019)

Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section
por: Martinez, Domingo Antonio Sanchez, et al.
Publicado: (2022)

The oncologists' and radiologists' PET
por: Weiss, Robin A
Publicado: (2003)

Geriatric assessment for oncologists
por: Korc-Grodzicki, Beatriz, et al.
Publicado: (2015)

Are We All Oncologists?
por: Malpas, J. S.
Publicado: (1984)

FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth
por: Slebe, Felipe, et al.
Publicado: (2016)

Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response
por: Martin Huertas, Roberto, et al.
Publicado: (2019)

Irreducible Dislocation of the Great Toe Interphalangeal Joint, Dorsal, and Plantar. Management and Long-term Evolution
por: García-Mata, Serafín, et al.
Publicado: (2023)

CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes
por: Dueñas, Marta, et al.
Publicado: (2012)

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
por: Colomer, R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_40s1b09m52o0p4g1inaollqv33